Compare OLLI & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLLI | CNTA |
|---|---|---|
| Founded | 1982 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 6.1B |
| IPO Year | 2015 | 2021 |
| Metric | OLLI | CNTA |
|---|---|---|
| Price | $79.68 | $39.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $139.31 | $43.17 |
| AVG Volume (30 Days) | 1.3M | ★ 1.5M |
| Earning Date | 06-02-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.43 | ★ 29.13 |
| EPS | ★ 3.89 | N/A |
| Revenue | ★ $2,649,198,000.00 | $15,000,000.00 |
| Revenue This Year | $15.62 | N/A |
| Revenue Next Year | $11.33 | N/A |
| P/E Ratio | $20.96 | ★ N/A |
| Revenue Growth | ★ 16.62 | N/A |
| 52 Week Low | $73.32 | $10.95 |
| 52 Week High | $141.74 | $40.26 |
| Indicator | OLLI | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 40.92 | 72.42 |
| Support Level | N/A | $39.36 |
| Resistance Level | $98.25 | $39.86 |
| Average True Range (ATR) | 3.24 | 0.14 |
| MACD | 0.22 | -0.30 |
| Stochastic Oscillator | 45.43 | 60.40 |
Ollie's Bargain Outlet Holdings Inc is a retailer of closeout merchandise and excess inventory. The company sells name brand household related items that consumers use in their everyday lives at prices that are heavily discounted below traditional retailers. It offers customers a broad selection of brand name products, including housewares, bed and bath, food, floor coverings, health and beauty aids, books and stationery, toys, and electronics. It operates stores across the Eastern half of the United States. Its differentiated go-to-market plan is characterized by a fun and engaging treasure hunt shopping experience, compelling customer value proposition, and witty, humorous in-store signage and advertising campaigns.
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.